[go: up one dir, main page]

DZ2826A1 - Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation. - Google Patents

Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation.

Info

Publication number
DZ2826A1
DZ2826A1 DZ990126A DZ990126A DZ2826A1 DZ 2826 A1 DZ2826 A1 DZ 2826A1 DZ 990126 A DZ990126 A DZ 990126A DZ 990126 A DZ990126 A DZ 990126A DZ 2826 A1 DZ2826 A1 DZ 2826A1
Authority
DZ
Algeria
Prior art keywords
intranasal
formulas
preparation
sildenafil mesylate
sildenafil
Prior art date
Application number
DZ990126A
Other languages
English (en)
Inventor
Anne Billotte
Brian Thomas Henry
Joanna Jayne Woods
Peter James Dunn
Peter Vallance Marshall
Original Assignee
Pfizer Res & Dev Company Nv I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Res & Dev Company Nv I filed Critical Pfizer Res & Dev Company Nv I
Application granted granted Critical
Publication of DZ2826A1 publication Critical patent/DZ2826A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ990126A 1998-06-22 1999-06-21 Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation. DZ2826A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DZ2826A1 true DZ2826A1 (fr) 2003-12-01

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990126A DZ2826A1 (fr) 1998-06-22 1999-06-21 Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation.

Country Status (40)

Country Link
US (2) US20020040139A1 (fr)
EP (1) EP0967214B1 (fr)
JP (1) JP3263379B2 (fr)
KR (1) KR100345824B1 (fr)
AP (1) AP1178A (fr)
AR (1) AR016993A1 (fr)
AT (1) ATE269866T1 (fr)
AU (1) AU746865B2 (fr)
BG (1) BG64372B1 (fr)
BR (1) BR9903273A (fr)
CA (1) CA2275554C (fr)
CZ (1) CZ294856B6 (fr)
DE (1) DE69918222T2 (fr)
DK (1) DK0967214T3 (fr)
DZ (1) DZ2826A1 (fr)
EA (1) EA001903B1 (fr)
ES (1) ES2221733T3 (fr)
GT (1) GT199900095A (fr)
HN (1) HN1999000096A (fr)
HR (1) HRP990195B1 (fr)
HU (1) HUP9902076A3 (fr)
ID (1) ID23554A (fr)
IL (1) IL130539A0 (fr)
IS (1) IS5085A (fr)
MA (1) MA25089A1 (fr)
MY (1) MY117967A (fr)
NO (1) NO317365B1 (fr)
NZ (1) NZ336382A (fr)
OA (1) OA11069A (fr)
PA (1) PA8476301A1 (fr)
PE (1) PE20000702A1 (fr)
PT (1) PT967214E (fr)
SG (1) SG77246A1 (fr)
SI (1) SI0967214T1 (fr)
SK (1) SK284574B6 (fr)
TN (1) TNSN99129A1 (fr)
TR (1) TR199901444A2 (fr)
TW (1) TWI223598B (fr)
UA (1) UA59385C2 (fr)
YU (1) YU29699A (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
CA2391968A1 (fr) * 1999-11-18 2001-05-25 Natco Pharma Limited Composition pharmaceutique amelioree pour traiter la dyserection masculine
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
EP1392262A1 (fr) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
JP2007516149A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 基板温度の均一性を制御する方法、および、内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006016530A1 (fr) * 2004-08-10 2006-02-16 Translational Research, Ltd. Composition transnasale dont l’action est immédiate et l’absorbabilité est élevée
EP1781360A1 (fr) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Dispositif de distribution de drogue par aérosol intégrant des conditionnements thermiques actionnés par percussion
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
KR101289917B1 (ko) 2004-10-18 2013-07-25 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 평활근을 이완시키기 위한 활성 성분을 함유하는 리포좀조성물, 이런 조성물의 생산 및 이의 치료적 용도
WO2006094924A2 (fr) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh Nouvelles compositions pharmaceutiques a base d'anticholinergiques et d'inhibiteurs de pde 5
EA016037B1 (ru) 2005-04-19 2012-01-30 Никомед Гмбх Рофлумиласт для лечения лёгочной гипертензии
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
KR20070067173A (ko) * 2005-08-29 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이정점 입도 분포를 갖는 고체 미립자 타달라필
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP2116264B1 (fr) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Préparation pour administration transnasale
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
WO2009098697A1 (fr) * 2008-02-08 2009-08-13 Dexxon Ltd. Formes pharmaceutiques de modafinil et de sildénafil
CA2756690C (fr) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration de compositions de benzodiazepine
US8747005B2 (en) 2008-06-04 2014-06-10 Colgate-Palmolive Company Oral care implement with cavitation system
WO2009152344A2 (fr) * 2008-06-11 2009-12-17 Comgenrx, Inc. Polythérapie à base d’inhibiteurs de phosphodiestérases
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
WO2011013003A2 (fr) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Granisétron pour administration intranasale et applicateur nasal
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
PL3415139T3 (pl) 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (fr) * 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
CA2795324C (fr) * 2012-11-09 2015-07-14 Purdue Pharma Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
EP3068397A1 (fr) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes
EP3108245B1 (fr) 2014-02-18 2020-07-22 Robert I. Henkin Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
NO2723977T3 (fr) 2014-03-19 2018-03-10
US20170035764A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
CN109996547A (zh) * 2016-10-31 2019-07-09 苏达有限公司 粘膜活性剂递送
CA3055094A1 (fr) * 2017-03-02 2018-09-07 Dutch Renewable Energy B.V. Administration intranasale de substances physiologiquement actives
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
SG11202006080SA (en) 2017-12-26 2020-07-29 Ftf Pharma Private Ltd Liquid oral formulations for pde v inhibitors
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2019200427A1 (fr) 2018-04-16 2019-10-24 Barista Mist Pty Ltd Compositions de caféine et procédés d'utilisation
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
WO2022026762A1 (fr) * 2020-07-29 2022-02-03 Lido Ventures Llc Appareil, système et procédé pour faciliter le traitement intranasal d'un patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
JP3348859B2 (ja) * 1995-11-20 2002-11-20 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃインヒビター
CA2291256A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter la dysfonction erectile
CA2312839C (fr) * 1997-12-02 2008-01-15 Lisbeth Illum Compositions pour administration nasale
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
CZ9902257A3 (cs) 2000-11-15
EA001903B1 (ru) 2001-10-22
DK0967214T3 (da) 2004-09-27
EA199900487A3 (ru) 2000-04-24
JP2000034232A (ja) 2000-02-02
SG77246A1 (en) 2000-12-19
NO993051D0 (no) 1999-06-21
NZ336382A (en) 1999-11-29
EP0967214A1 (fr) 1999-12-29
TR199901444A2 (xx) 2000-01-21
BG64372B1 (bg) 2004-12-30
HRP990195A2 (en) 2000-02-29
HN1999000096A (es) 2000-12-03
IS5085A (is) 1999-12-23
DE69918222D1 (de) 2004-07-29
MA25089A1 (fr) 2000-12-31
YU29699A (sh) 2003-02-28
CA2275554C (fr) 2003-06-03
BR9903273A (pt) 2000-05-09
KR20000006310A (ko) 2000-01-25
PE20000702A1 (es) 2000-08-16
TNSN99129A1 (fr) 2005-11-10
JP3263379B2 (ja) 2002-03-04
UA59385C2 (uk) 2003-09-15
HUP9902076A2 (hu) 2000-05-28
HRP990195B1 (en) 2003-04-30
AP9901585A0 (en) 1999-06-30
SK284574B6 (sk) 2005-06-02
TWI223598B (en) 2004-11-11
SK81999A3 (en) 2001-01-18
NO993051L (no) 1999-12-23
AR016993A1 (es) 2001-08-01
ID23554A (id) 2000-05-04
NO317365B1 (no) 2004-10-18
OA11069A (en) 2002-03-13
US20020040139A1 (en) 2002-04-04
CA2275554A1 (fr) 1999-12-22
ATE269866T1 (de) 2004-07-15
KR100345824B1 (ko) 2002-07-24
HUP9902076A3 (en) 2002-03-28
IL130539A0 (en) 2000-06-01
GT199900095A (es) 2000-12-13
AU746865B2 (en) 2002-05-02
PT967214E (pt) 2004-08-31
US20030158206A1 (en) 2003-08-21
EP0967214B1 (fr) 2004-06-23
SI0967214T1 (en) 2004-10-31
AU3579499A (en) 2000-01-06
MY117967A (en) 2004-08-30
AP1178A (en) 2003-06-30
EA199900487A2 (ru) 1999-12-29
CZ294856B6 (cs) 2005-03-16
BG103510A (en) 2000-01-31
HU9902076D0 (en) 1999-08-30
PA8476301A1 (es) 2000-09-29
DE69918222T2 (de) 2005-07-28
ES2221733T3 (es) 2005-01-01

Similar Documents

Publication Publication Date Title
DZ2826A1 (fr) Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation.
DZ2712A1 (fr) Composition de mésylate de trovafloxacine et procédé pour sa préparation.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2781234B1 (fr) Emulsions de bitume, procede pour leur obtention, et compositions les contenant
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
DZ2962A1 (fr) Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
EP1093448A4 (fr) Procede de preparation de mousses ceramiques
NO20006039L (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
MA24484A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .
DZ3049A1 (fr) Suspensions de ziprasidone nouvelles et procédé pour leur préparation.
DZ2912A1 (fr) Procédé pour la préparation de pyrazolo Ä4,3-DÜpyrimidine-7-ones, et intermédiaires pour ce procédé.
EP1222865A4 (fr) Ingredient pour cigarette et procede de fabrication
FI964572L (fi) Prosessi propeenin homo- tai kopolymeerien valmistamiseksi
HUP0003737A3 (en) New process for the preparation of omeprazole
DZ2658A1 (fr) Formulations nouvelles de paroxétine et procédé pour leur préparation.
NO995287L (no) Forbedret fremgangsmõte for fremstilling av sjokolade
DZ2677A1 (fr) Compositions nouvelles renfermant des dérivés de benzopyranne et pyridopyranne et procédé pour leur préparation.
FR2773558B1 (fr) Procede pour l'obtention de 1-butene
DZ2607A1 (fr) Procédé pour la synthése de dérivés de quinoléine pharmaceutiquement actifs.